Sang-Hoon Kim
President chez BUKWANG PHARMACEUTICAL CO., LTD.
Fortune : 3 M $ au 30/04/2024
Profil
Sang-Hoon Kim is currently working as the Co-President, Director & Chief Strategy Officer at Bukwang Pharmaceutical Co., Ltd.
He is also a Director at Contera Pharma ApS and Dyna Therapeutics Co., Ltd.
Mr. Kim completed his undergraduate degree at Boston University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2022 | 568 504 ( 0,83% ) | 3 M $ | 30/04/2024 |
Postes actifs de Sang-Hoon Kim
| Sociétés | Poste | Début |
|---|---|---|
| BUKWANG PHARMACEUTICAL CO., LTD. | President | 15/03/2013 |
Contera Pharma ApS
 Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Directeur/Membre du Conseil | - |
| Dyna Therapeutics Co., Ltd. | Directeur/Membre du Conseil | - |
Formation de Sang-Hoon Kim
| Boston University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BUKWANG PHARMACEUTICAL CO., LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Contera Pharma ApS
Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
| Dyna Therapeutics Co., Ltd. |
